Home » Clinical Performance of the T2Candida Panel
Clinical Performance of the T2Candida Panel
Cornelius J. Clancy, M.D, University of Pittsburgh, presents on the strong clinical performance of the T2Candida Panel
The T2Candida Panel detects infections missed by blood culture and demonstrates consistently strong performance.
As reported by Cornelius J. Clancy, M.D., Associate Professor of Medicine, Director, Mycology Program, University of Pittsburgh.
T2Candida Panel identified 37 cases of Candida infections missed by companion blood cultures for patients receiving antifungal therapy in a multi-center DIRECT2 study.
Findings suggest that T2Candida is more sensitive than blood culture, especially in the presence of antifungal treatment, and a more effective diagnostic tool for patients treated with pre-emptive or empiric antifungal therapy.
Accumulating data for T2Candida’s performance in clinical practice demonstrates a sensitivity at about 90% and specificity ranging from 98% to 99%.
JOIN THE MAILING LIST!
T2 BIOSYSTEMS OVERVIEW
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.